Insider Selling: Alder Biopharmaceuticals Inc (ALDR) COO Sells 1,434 Shares of Stock

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) COO Erin Lavelle sold 1,434 shares of the company’s stock in a transaction dated Thursday, April 25th. The shares were sold at an average price of $13.67, for a total transaction of $19,602.78. Following the completion of the transaction, the chief operating officer now directly owns 5,842 shares in the company, valued at approximately $79,860.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of NASDAQ:ALDR opened at $13.96 on Friday. The company has a market capitalization of $956.26 million, a P/E ratio of -2.87 and a beta of 2.80. Alder Biopharmaceuticals Inc has a fifty-two week low of $9.44 and a fifty-two week high of $20.87. The company has a debt-to-equity ratio of 1.66, a quick ratio of 14.87 and a current ratio of 14.87.

A number of research analysts have commented on ALDR shares. Zacks Investment Research cut shares of Alder Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, February 1st. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $14.00 target price on shares of Alder Biopharmaceuticals in a research report on Tuesday, February 26th. BidaskClub cut shares of Alder Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 11th. Finally, Canaccord Genuity reduced their price target on shares of Alder Biopharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, March 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $21.09.

A number of large investors have recently modified their holdings of ALDR. TIAA CREF Investment Management LLC raised its holdings in Alder Biopharmaceuticals by 748.3% in the third quarter. TIAA CREF Investment Management LLC now owns 1,049,133 shares of the biopharmaceutical company’s stock valued at $17,468,000 after acquiring an additional 925,463 shares in the last quarter. Samlyn Capital LLC increased its stake in Alder Biopharmaceuticals by 47.2% in the fourth quarter. Samlyn Capital LLC now owns 2,818,788 shares of the biopharmaceutical company’s stock valued at $28,892,000 after purchasing an additional 904,098 shares during the last quarter. BB Biotech AG increased its stake in Alder Biopharmaceuticals by 22.1% in the fourth quarter. BB Biotech AG now owns 2,766,008 shares of the biopharmaceutical company’s stock valued at $28,352,000 after purchasing an additional 500,000 shares during the last quarter. Man Group plc increased its stake in Alder Biopharmaceuticals by 233.7% in the third quarter. Man Group plc now owns 513,491 shares of the biopharmaceutical company’s stock valued at $8,550,000 after purchasing an additional 359,602 shares during the last quarter. Finally, Millennium Management LLC increased its stake in Alder Biopharmaceuticals by 168.5% in the fourth quarter. Millennium Management LLC now owns 477,310 shares of the biopharmaceutical company’s stock valued at $4,892,000 after purchasing an additional 299,538 shares during the last quarter.

WARNING: “Insider Selling: Alder Biopharmaceuticals Inc (ALDR) COO Sells 1,434 Shares of Stock” was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/04/27/insider-selling-alder-biopharmaceuticals-inc-aldr-coo-sells-1434-shares-of-stock.html.

About Alder Biopharmaceuticals

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.

See Also: Growth Stocks, What They Are, What They Are Not

Insider Buying and Selling by Quarter for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.